Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Cancer device reaches 12 U.S. centers as RenovoRx readies trial finish
RenovoRx reported full-year 2025 revenue of $1.1 million for its RenovoCath device, a significant increase from 2024, with 12 U.S. cancer centers actively utilizing the device and 21 more evaluating it. The company’s Phase III TIGeR-PaC trial is on track for enrollment completion by mid-2026, with final data anticipated in 2027. RenovoRx also strengthened its financial position with a $10 million private placement, bringing its cash on hand to approximately $13 million.